Guidelines for Stability Studies of Biosimilars as per EMA Guidelines
1) Purpose
The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for conducting stability studies for biosimilars in accordance with the European Medicines Agency (EMA) guidelines. This SOP ensures that stability data supports the quality, safety, and efficacy of biosimilars throughout their shelf life.
2) Scope
This SOP applies to all personnel involved in the design, execution, and documentation of stability studies for biosimilars intended for the European market.
3) Responsibilities
Stability Testing Team: Responsible for conducting stability studies and documenting results in compliance with EMA guidelines.
Quality Assurance (QA) Team: Responsible for reviewing and approving stability study protocols and reports.
Regulatory Affairs Team: Responsible for ensuring that stability studies meet EMA regulatory expectations.
4) Procedure
4.1 Preparation for Stability Testing
4.1.1 Obtain and review the latest EMA guidelines for stability testing of biosimilars.
4.1.2 Develop a
4.2 Selection of Batches and Samples
4.2.1 Select representative batches of the biosimilar product, typically three primary batches manufactured using the proposed production process.
4.2.2 Prepare sufficient samples to cover the entire study duration, considering the number of
4.3 Defining Storage Conditions and Time Points
4.3.1 Define the storage conditions according to EMA guidelines, typically including:
- Long-term stability: 5°C ± 3°C or 25°C ± 2°C/60% RH ± 5% RH, depending on the product type
- Accelerated stability: 40°C ± 2°C/75% RH ± 5% RH
4.3.2 Establish the time points for sampling, such as 0, 3, 6, 9, 12, 18, and 24 months for long-term studies, and additional time points for accelerated studies.
4.4 Conducting Stability Tests
4.4.1 Store samples under the defined conditions, monitoring temperature and humidity to ensure compliance with the set parameters.
4.4.2 At each specified time point, remove samples and conduct stability-indicating tests, including physical, chemical, microbiological, and functional tests, as applicable.
4.4.3 Record all results meticulously in stability data sheets, ensuring accuracy and traceability of data.
5) Abbreviations, if any
EMA: European Medicines Agency
QA: Quality Assurance
6) Documents, if any
Stability protocol, stability data sheets, stability testing records, stability report, submission package to EMA.
7) Reference, if any
EMA Guidelines on Stability Testing of Biosimilars.
8) SOP Version
Version 1.0